JP4607920B2 - 心臓内薬物送達 - Google Patents
心臓内薬物送達 Download PDFInfo
- Publication number
- JP4607920B2 JP4607920B2 JP2007139899A JP2007139899A JP4607920B2 JP 4607920 B2 JP4607920 B2 JP 4607920B2 JP 2007139899 A JP2007139899 A JP 2007139899A JP 2007139899 A JP2007139899 A JP 2007139899A JP 4607920 B2 JP4607920 B2 JP 4607920B2
- Authority
- JP
- Japan
- Prior art keywords
- catheter
- drug
- heart
- treatment
- needle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000012377 drug delivery Methods 0.000 title claims description 37
- 210000002216 heart Anatomy 0.000 claims description 119
- 239000003814 drug Substances 0.000 claims description 101
- 229940079593 drug Drugs 0.000 claims description 88
- 239000003102 growth factor Substances 0.000 claims description 42
- 230000004044 response Effects 0.000 claims description 25
- 230000002107 myocardial effect Effects 0.000 claims description 18
- 230000000747 cardiac effect Effects 0.000 claims description 14
- 230000005855 radiation Effects 0.000 claims description 14
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 230000002491 angiogenic effect Effects 0.000 claims description 6
- 238000004891 communication Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 description 28
- 230000035899 viability Effects 0.000 description 28
- 210000004165 myocardium Anatomy 0.000 description 27
- 239000002775 capsule Substances 0.000 description 26
- 238000001647 drug administration Methods 0.000 description 25
- 230000007246 mechanism Effects 0.000 description 24
- 230000000302 ischemic effect Effects 0.000 description 19
- 239000000306 component Substances 0.000 description 14
- 210000005003 heart tissue Anatomy 0.000 description 14
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 13
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 13
- 229940124597 therapeutic agent Drugs 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- 230000033115 angiogenesis Effects 0.000 description 11
- 230000003111 delayed effect Effects 0.000 description 10
- 210000001174 endocardium Anatomy 0.000 description 9
- 230000000250 revascularization Effects 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 238000002604 ultrasonography Methods 0.000 description 9
- 238000013459 approach Methods 0.000 description 8
- 230000033001 locomotion Effects 0.000 description 8
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 7
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 7
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 208000028867 ischemia Diseases 0.000 description 6
- 238000013507 mapping Methods 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 208000031225 myocardial ischemia Diseases 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 229940126864 fibroblast growth factor Drugs 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000033764 rhythmic process Effects 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000008081 blood perfusion Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000001678 irradiating effect Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 2
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 210000000779 thoracic wall Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000746181 Therates Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 108010016628 ameroid Proteins 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000000283 vasomotion Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Landscapes
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Description
図上に印をつけられ(marked)、ここに薬物がカテーテルにより注入されることになる。好ましくは、地図および格子は、位置座標に関連して集められた局所組織の生存能力を示す心臓の生理学的活動性を基礎として決定される。
ズ(M. Simons)を参照)。
心臓内のカテーテルの位置に応答して信号を発する最低1個の位置センサー;および
位置センサーからの信号に応答して決定される部位で所望の用量の治療薬を投与する薬物送達装置、
を包含する。
心壁への治療的治療(therapeutic treatment)の投与のため心室に挿入されるカテーテル;
心壁の厚さに応答した信号を発するセンサー;および
センサーからの信号を受領しそして心壁の厚さに応答して治療を制御する制御装置、
を包含する、心臓内治療のための装置がさらに提供される。
カテーテルを心室に導入すること;
カテーテルの位置座標を感知すること;
座標を使用してカテーテルを所望の部位での心壁との接触に位置を定めること;そして
カテーテルを使用してその部位で治療薬を投与すること、
を包含する、心臓内薬物投与方法がさらに提供される。
心壁の厚さの変動を示す信号を受領すること;そして
厚さの変動に応答して心壁のある部位に治療的治療を投与すること、を包含する、心臓内治療方法が加えて提供される。
ンプを含みうる。あるいは、分注器54は、当該技術分野で同様に既知であるようなカテーテルを通る溜めからのマイクロカプセルの通過を制御するための別個の供給装置を含みうる。マイクロカプセルは、例えば下の図6Aに示されかつそれへの言及でさらに記述されるとおり、心筋中に埋込まれる。
Claims (9)
- 心壁へ血管新生性成長因子を含む薬物による治療を施すため心室に挿入されるカテーテル(64、78);
心壁の厚さの変動に応答した信号を発するセンサー(32、60);
および
センサーからの信号を受領しそして心壁の厚さの変動に応答して治療を制御する制御装置(50)、
を含んで成る、心臓内治療のための装置。 - センサーが超音波変換器を含んで成る、請求項1に記載の装置。
- 変換器がその遠位端部に隣接してカテーテルに固定される、請求項2に記載の装置。
- センサーが、その遠位端部に隣接してカテーテルに固定される位置センサーを含んで成る、請求項1に記載の装置。
- カテーテルが薬物送達装置を含んで成り、また、治療が心壁のある部位での血管新生性成長因子を含む薬物の投与を含んで成る、請求項1−4のいずれかに記載の装置。
- 輻射源を含み、治療が、輻射源を使用する心筋組織の照射を含んで成り、また、カテーテルが輻射源と連絡する導波管を含んで成る、請求項1−5のいずれかに記載の装置。
- 制御装置が、治療が心周期の一部分の間に施されるように治療を制御する、請求項1−6のいずれかに記載の装置。
- 制御装置が、治療が心壁の厚さが最大である場合に施されるように治療を制御する、請求項7に記載の装置。
- 制御装置が、治療が心壁の厚さが最小である場合に施されるように治療を制御する、請求項7に記載の装置。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007139899A JP4607920B2 (ja) | 2007-05-28 | 2007-05-28 | 心臓内薬物送達 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007139899A JP4607920B2 (ja) | 2007-05-28 | 2007-05-28 | 心臓内薬物送達 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54819699A Division JP4535468B2 (ja) | 1998-02-05 | 1998-02-05 | 心臓内薬物送達 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007301380A JP2007301380A (ja) | 2007-11-22 |
JP4607920B2 true JP4607920B2 (ja) | 2011-01-05 |
Family
ID=38835798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007139899A Expired - Lifetime JP4607920B2 (ja) | 2007-05-28 | 2007-05-28 | 心臓内薬物送達 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4607920B2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5432473B2 (ja) * | 2008-05-02 | 2014-03-05 | オリンパス株式会社 | 薬液投与装置 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0808607A1 (de) * | 1996-05-24 | 1997-11-26 | Sulzer Osypka GmbH | Vorrichtung zum Perforieren der Herzwand |
JP2001509036A (ja) * | 1996-01-08 | 2001-07-10 | バイオセンス・インコーポレイテッド | 心筋の脈管再生方法および装置 |
-
2007
- 2007-05-28 JP JP2007139899A patent/JP4607920B2/ja not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001509036A (ja) * | 1996-01-08 | 2001-07-10 | バイオセンス・インコーポレイテッド | 心筋の脈管再生方法および装置 |
EP0808607A1 (de) * | 1996-05-24 | 1997-11-26 | Sulzer Osypka GmbH | Vorrichtung zum Perforieren der Herzwand |
US5964754A (en) * | 1996-05-24 | 1999-10-12 | Sulzer Osypka Gmbh | Device for perforating the heart wall |
Also Published As
Publication number | Publication date |
---|---|
JP2007301380A (ja) | 2007-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4535468B2 (ja) | 心臓内薬物送達 | |
US6309370B1 (en) | Intracardiac drug delivery | |
CA2316568C (en) | Intracardiac cell delivery and cell transplantation | |
US20030113303A1 (en) | Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances | |
US20030125615A1 (en) | Homing of autologous cells to a target zone in tissue using active therapeutics or substances | |
EP1415660A1 (en) | Homing donor cells to a target zone in tissue for delivery of translocation stimulators | |
EP1229845A2 (en) | Method and apparatus for demand injury in stimulating angiogenesis | |
AU748491B2 (en) | Intracardiac drug delivery | |
JP4607920B2 (ja) | 心臓内薬物送達 | |
IL132073A (en) | Intracardiac drug delivery apparatus and method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20080527 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20081009 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090616 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090916 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090924 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100302 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100628 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100707 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100928 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101007 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131015 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |